On this episode of Molecular Moments, Lynn Kamen, Ph.D., and Michelle Miller, Ph.D. DABT discuss their very different journeys to
BioAgilytix, a leading global contract research organization focused on supporting its pharmaceutical and biotech partners in all stages of drug development, recently acquired MicroConstants and 360biolabs®️. These acquisitions greatly expand the already impressive scope of BioAgilytix’s capabilities, scientific expertise and geographic footprint. As an independent bioanalytical testing industry leader, MicroConstants, now known as BioAgilytix San Diego, has been providing Good Laboratory Practice (GLP) compliant services for decades. Headquartered in San
Tell us a little about your background and how you came to join BioAgilytix. My first wet lab experience was gained during my undergrad studies at Bowdoin College in southern Maine. I majored in biology and completed an honors thesis through an exploratory study of an uncharacterized genetic locus in a pathogenic yeast. Thereafter, I moved to Boston and worked for three years at the Ragon Institute of
Tell us a little about your background and how you came to join BioAgilytix. I did my doctoral and postdoctoral training in Cell Biology. My fascination with blood and lymphatic vessels led me to research their genetic make-up and related diseases, in hopes to find potential drug targets. During my research I trained extensively in cell-based work including but not limited to gene expression studies, intracellular signaling, cellular
Tell us a little about your background and how you came to join BioAgilytix. Some of my friends at my previous job joined BAL and told me about how much they liked it here. What is your current role, and how has it evolved since joining the team? Scientist III/BPM. Since joining the team I’ve had 4 analysts and scientists added under me. Along with that I’ve been given the
As a leading contract research organization (CRO), BioAgilytix helps companies around the world with research and development, leveraging expertise in cell-based assays, immunogenicity, biomarkers and pharmacokinetics. We perform assay development and validation as well as sample analysis, lot release testing and ongoing data surveillance after drug products are introduced to market. Committed to helping reduce drug development timelines and costs, we are not alone in this growing industry. In fact,
The best science demands the best people—and at BioAgilytix’s Boston lab, there’s no shortage of skilled and dedicated scientists. Get to know one of our expert flow cytometry scientists and longtime Boston team member, Benjamin Lamothe.
In our recruitment process we are often asked by those coming from pharma & biotech careers, “what’s a day in the life like at a CRO?” Who better to ask than our own team members who have made the career transition themselves? We start the discussion with Dr. Jim McNally.
We recently sat down with Dr. Jim McNally for a Q&A to hear his “Behind the Science” perspectives on the industry and where he thinks BioAgilytix brings the most value to pharma & biotech customers.
Did you know that our new General Manager, Europe, Dr. Frank Horling, was a client of BioAgilytix before joining our team? We asked him to share his perspectives on what it was like to be a BioAgilytix customer as well as what motivated him to join our lab in Hamburg, Germany.
When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable of handling quick turnarounds and rescue projects. We look at an example of how BioAgilytix sprung to action to transform a troubled study.